For the 2023 PharmaVoice Year in Preview, the authors asked industry executives to look into their crystal balls and tell them about anything they see coming. As they culled responses, several themes emerged: changes within the clinic, a digital transformation, fluidity in valuation and capital investments, regulatory shifts and more.
InsightRX’s CEO and Co-founder, Sirj Goswami, PhD, provides his prediction on the impact of Project Optimus, an initiative by the FDA, in this article from PharmaVoice*.
Want more information about Project Optimus? Click here to read an article, published by Applied Clinical Trials, that discusses this initiative and its recommendation to change how doses are selected during oncology clinical trials and post-approval studies.
*About PharmaVoice
PharmaVoice is a leading industry publication for life sciences executives and other healthcare-service related professionals. Stories deliver the most important voices and ideas in the life sciences to industry leaders.
